Research Facility

St Louis, Missouri 63141

2 studies enrolling now · 11 studies all time

What they study most

Advanced Breast Cancer, Anemia, Carcinoid, Carcinoid Tumor, Chronic Kidney Disease, Chronic Pain, Chronic Renal Failure, ER+ Breast Cancer, GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Glioblastoma

Studies at this site

• Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs. — Recruiting now
• Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy — Recruiting now
• Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC — Running, not enrolling
• Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs. — Running, not enrolling
• Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma — Completed
• A Comparison of Once a Day Dose Compared to 2 Doses/Day — Completed
• A Double Blind Study for the Treatment of Acute Ulcerative Colitis — Completed
• Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis — Completed
• Safety of Buprenorphine Transdermal Patch (BTDS) in Osteoarthritis Pain: a 52-Week Extension Phase — Stopped early
• Buprenorphine Transdermal System (BTDS) in Subjects w/Mod-sev Osteoarthritis (OA) Chronic Pain of Knee — Completed
• Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Chronic Low Back Pain — Completed